| Name | Title | Contact Details |
|---|
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics.
Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.
Hanson Research is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.